Biotechnology

Printers capable of generating functional capillary networks within lab-grown organs.

G42 Healthcare operates Abu Dhabi's population-scale genomics program, combining AI analysis with clinical data to build the region's most advanced precision medicine platform.

Mexico is the 8th-largest medical device exporter globally, manufacturing Class II/III devices including surgical instruments, catheters, and diagnostic equipment in Baja California clusters.

Olympus controls ~70% of the global gastrointestinal endoscope market — integrating AI-assisted diagnosis for real-time cancer detection.

ML models flagging toxicity and safety issues during clinical trials.

Japan's status as the world's most aged society (29% over 65) drives innovation in telemedicine, wearable monitoring, and dementia care technology.

African-built AI models trained on African patient data detect TB, malaria, cervical cancer, and diabetic retinopathy from phone cameras and portable ultrasound devices.

AstraZeneca paid $5.2 billion for access to CSPC's AI drug discovery platform — the largest AI-pharma deal in history — signaling China's emergence in computational drug design

AlphaFold 3 and RoseTTAFold All-Atom predict protein-drug interactions, while David Baker's lab designs entirely novel proteins with therapeutic and industrial applications that don't exist in nature.

Generative models for de novo protein design and cell behavior prediction.

Israeli companies like Aidoc and Zebra Medical have FDA-cleared AI systems that detect strokes, cancers, and fractures from CT/MRI scans in real-time clinical workflows.

Fujitsu and Japanese pharma companies are deploying AI to accelerate clinical research and address Japan's 'drug loss' crisis — domestic drug approvals lagging global standards.

Recursion Pharmaceuticals, Insilico Medicine, and Isomorphic Labs (DeepMind) are using AI to design novel drug molecules, with multiple AI-discovered compounds now in human clinical trials.

Canadian institutes are combining world-class AI research with biomedical data to build drug discovery platforms, including CIFAR-funded work on spatial genomics for brain tumors and molecular modeling.

Isomorphic Labs (UK, $600M) using DeepMind's AlphaFold to predict protein structures and design drugs computationally — preparing first clinical trials

Voice AI that automatically documents patient care in nursing and clinical settings — reducing administrative burden on healthcare workers by 40%+

Korean companies Lunit, Vuno, and Coreline Soft lead in AI-powered medical imaging diagnostics, with FDA-cleared products deployed in 4,000+ hospitals across 50 countries.

Mexican healthtech startups deploy ML models for medical imaging analysis, patient outcome prediction, and treatment optimization in hospitals serving underserved populations.

Harrison.AI develops clinical-grade AI models for radiology and pathology that match specialist accuracy — deployed across Australian hospitals and highlighted in the National AI Plan as a sovereign capability.

Australian deep tech company Algenie is engineering algae as production platforms for high-value compounds — from pharmaceuticals to bioplastics — using Australia's abundant sunlight as the primary energy input.

Alpha Tau Medical's Alpha DaRT technology uses controlled alpha-radiation diffusion to destroy solid tumors while sparing surrounding tissue, in clinical trials globally.

Korean biotech companies LigaChem, AimedBio, and others are developing next-generation ADC platforms, with Boehringer Ingelheim licensing AimedBio's technology in a deal worth up to $991M.

Vietnam's national aquaculture genetics programs develop disease-resistant, fast-growing strains of pangasius and shrimp using selective breeding and genomic selection technology.

Aravind Eye Hospital performs 500,000+ eye surgeries annually at costs from $12-$100 — using a McDonald's-inspired assembly-line model that achieves clinical outcomes matching the best Western hospitals at 1/100th the cost.